Australian company Technovalia and its partners Chulalongkorn University and BioNet have announced ethics approval for a phase 2 trial of the ChulaCov19 BNA159 mRNA vaccine as a booster dose in adults.
Australian launch for phase 2 trial of new mRNA vaccine
November 21, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News -
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 - - Australian Biotech -
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 - - Australian Biotech -
AI has to be seen as a generational opportunity to get medicines to patients faster
August 10, 2025 - - Latest News